Thyroid Ultrasound, Fine-Needle Aspiration Linked to Thyroid Cancer Incidence
the Cancer Therapy Advisor take:
An increased incidence of thyroid cancer may be the result of increased use of thyroid ultrasound and fine-needle aspiration (FNA), according to a Veterans Affairs (VA) study published in Cancer.
Jose Zevallos, MD, MPH, FACS, and colleagues at the University of North Carolina at Chapel Hill examined VA administrative data from 2000 to 2012, hypothesizing that incidence of thyroid cancer would correspond to increases in ultrasound and FNA modalities.
The researchers found a jump in thyroid cancer incidence per 100,000 individuals, from 10.3 in 2000 to 21.5 in 2012. At the same time, rate of thyroid ultrasound use jumped from 125.6 in 2001 to 572.1 in 2012, while FNA went from 7 in 200 to 46 in 2012.
There was a statistically significant increase in thyroid cancer incidence from 2000 to 2008, followed by more pronounced increase from 2008 to 2012, which corresponded with an increase in thyroid ultrasound use from 2002 to 2012 and FNA from 2000 to 2012.
“These findings suggest that the increase in thyroid cancer incidence may be related to increases in the use of thyroid ultrasound and FNA,” the authors concluded.
An increased incidence of thyroid cancer may be the result of increased use of thyroid ultrasound and fine-needle aspiration.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- FDA Grants Priority Review to Afatinib for Uncommon EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC
- Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer
- Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC